{"id":"ifosfamide-mesna","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (encephalopathy)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ifosfamide works by forming covalent bonds between DNA strands, preventing replication and transcription in rapidly dividing cancer cells. Mesna is a uroprotective agent that binds to acrolein and other toxic metabolites of ifosfamide in the urine, reducing hemorrhagic cystitis and other urinary tract toxicities without compromising the anticancer activity.","oneSentence":"Ifosfamide is an alkylating agent that cross-links DNA to kill cancer cells, while mesna is a protective agent that binds to toxic metabolites to reduce bladder toxicity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:33.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoma (as part of combination chemotherapy regimen in phase 3 study)"}]},"trialDetails":[{"nctId":"NCT05813327","phase":"PHASE1","title":"Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-03-14","conditions":"Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue","enrollment":6},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT07389356","phase":"NA","title":"Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-25","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":70},{"nctId":"NCT02106988","phase":"PHASE2","title":"Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-16","conditions":"Lymphoma","enrollment":40},{"nctId":"NCT04425070","phase":"PHASE1, PHASE2","title":"A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2020-08-18","conditions":"Peripheral T-cell Lymphoma, NK/T-cell Lymphoma","enrollment":56},{"nctId":"NCT04224337","phase":"PHASE2","title":"Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-06-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":16},{"nctId":"NCT04881240","phase":"PHASE1","title":"Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-02-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL","enrollment":60},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT01864109","phase":"PHASE2","title":"Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":"Newly Diagnosed Ewing Sarcoma","enrollment":83},{"nctId":"NCT04897321","phase":"PHASE1","title":"B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-07-06","conditions":"Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma","enrollment":32},{"nctId":"NCT04318678","phase":"PHASE1","title":"CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-07-29","conditions":"AML/MDS, B-ALL, T-ALL","enrollment":108},{"nctId":"NCT03805022","phase":"PHASE3","title":"Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2019-02-14","conditions":"Non-metastatic Soft-tissue Sarcoma, Resectable","enrollment":351},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT06341998","phase":"PHASE2, PHASE3","title":"Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children","status":"COMPLETED","sponsor":"Shandong First Medical University","startDate":"2020-06-01","conditions":"Germ Cell Tumor, Yolk Sac Tumor","enrollment":32},{"nctId":"NCT04947501","phase":"EARLY_PHASE1","title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-06-22","conditions":"Neuroblastoma, Pediatric Cancer","enrollment":26},{"nctId":"NCT00878254","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-03-25","conditions":"Mantle-Cell Lymphoma","enrollment":25},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT01873326","phase":"PHASE2","title":"Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-06","conditions":"Germ Cell Tumors","enrollment":92},{"nctId":"NCT05705687","phase":"NA","title":"Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-05-05","conditions":"Non-Seminomatous Germ Cell Tumor","enrollment":150},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT06593899","phase":"PHASE2","title":"The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-05-01","conditions":"Soft Tissue Sarcomas","enrollment":51},{"nctId":"NCT00936936","phase":"PHASE2","title":"High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06-02","conditions":"Testicular Cancer","enrollment":64},{"nctId":"NCT02049905","phase":"PHASE3","title":"Phase 3 Study to Treat Patients With Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2014-01","conditions":"Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma","enrollment":433},{"nctId":"NCT02235701","phase":"PHASE1, PHASE2","title":"Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2014-09-02","conditions":"Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma","enrollment":70},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT06236789","phase":"","title":"Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2016-11","conditions":"Prostatic Neoplasm","enrollment":60},{"nctId":"NCT00006734","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2001-05","conditions":"Sarcoma","enrollment":587},{"nctId":"NCT00346125","phase":"NA","title":"PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-04-10","conditions":"Sarcoma","enrollment":70},{"nctId":"NCT03064867","phase":"PHASE1, PHASE2","title":"Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Molly Gallogly","startDate":"2017-06-26","conditions":"Diffuse Large B-cell-lymphoma","enrollment":65},{"nctId":"NCT00432094","phase":"PHASE2","title":"Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-12-19","conditions":"Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma","enrollment":23},{"nctId":"NCT01481272","phase":"PHASE2","title":"Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients","status":"COMPLETED","sponsor":"Polish Lymphoma Research Group","startDate":"2011-11","conditions":"Diffuse Large B Cell Lymphoma","enrollment":77},{"nctId":"NCT02732015","phase":"PHASE2","title":"Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-12","conditions":"Locally Advanced Sarcoma","enrollment":37},{"nctId":"NCT00324467","phase":"PHASE2","title":"Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT03651375","phase":"PHASE2","title":"Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2017-02-11","conditions":"Sarcoma, Fibrosarcoma, Leiomyosarcoma","enrollment":46},{"nctId":"NCT04699214","phase":"PHASE2","title":"Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment","status":"UNKNOWN","sponsor":"Yong Chen","startDate":"2020-09-01","conditions":"Other Disorders of Soft Tissues","enrollment":210},{"nctId":"NCT01169636","phase":"PHASE1, PHASE2","title":"Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-31","conditions":"Hodgkin's Lymphoma","enrollment":62},{"nctId":"NCT03283696","phase":"PHASE1","title":"A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-10-18","conditions":"Soft Tissue Sarcoma","enrollment":24},{"nctId":"NCT03593902","phase":"PHASE2, PHASE3","title":"Cardiac Safe Transplants for Systemic Sclerosis","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2018-05-17","conditions":"Systemic Sclerosis, Scleroderma","enrollment":9},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT01329900","phase":"PHASE2","title":"Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-08-22","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT00787722","phase":"PHASE1, PHASE2","title":"Hematopoietic Stem Cell Transplant in Devic's Disease","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2009-10-10","conditions":"Devic's Disease","enrollment":13},{"nctId":"NCT00354744","phase":"PHASE3","title":"High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2006-07","conditions":"Sarcoma","enrollment":109},{"nctId":"NCT03829566","phase":"PHASE2, PHASE3","title":"Autologous Transplant To End NMO Spectrum Disorder","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-11","conditions":"Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder","enrollment":""},{"nctId":"NCT04154735","phase":"PHASE2","title":"Autologous Transplant Targeted Against Crohn's","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-11","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02441309","phase":"PHASE2","title":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2014-10","conditions":"Osteosarcoma","enrollment":8},{"nctId":"NCT00137995","phase":"PHASE3","title":"R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-06","conditions":"Lymphoma, Large-Cell, Diffuse","enrollment":481},{"nctId":"NCT00061893","phase":"PHASE2","title":"Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-04","conditions":"Sarcoma","enrollment":38},{"nctId":"NCT00231842","phase":"PHASE2","title":"Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2003-02","conditions":"Uterine Cancer","enrollment":30},{"nctId":"NCT00002565","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1994-05-25","conditions":"Lymphoma","enrollment":61},{"nctId":"NCT00822848","phase":"PHASE1","title":"Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2009-02","conditions":"Sarcoma","enrollment":18},{"nctId":"NCT00002865","phase":"PHASE2","title":"High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"1995-04","conditions":"Leukemia","enrollment":25},{"nctId":"NCT01696669","phase":"PHASE2","title":"Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults","status":"COMPLETED","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2010-03-30","conditions":"Ewing's Sarcoma","enrollment":43},{"nctId":"NCT02371161","phase":"PHASE2","title":"Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-02","conditions":"Non Hodgkin Lymphoma","enrollment":135},{"nctId":"NCT01453205","phase":"PHASE2","title":"A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-02-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":187},{"nctId":"NCT02164097","phase":"PHASE1","title":"ODSH + ICE Chemotherapy in Pediatric Solid Tumors","status":"TERMINATED","sponsor":"New York Medical College","startDate":"2015-01","conditions":"Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma","enrollment":4},{"nctId":"NCT00623077","phase":"PHASE1","title":"MT2004-30: Tomotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08","conditions":"Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer","enrollment":23},{"nctId":"NCT02408042","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)","status":"WITHDRAWN","sponsor":"Western Regional Medical Center","startDate":"2015-04","conditions":"Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT01226849","phase":"PHASE1","title":"Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2010-11","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":6},{"nctId":"NCT03105596","phase":"PHASE2","title":"Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)","status":"UNKNOWN","sponsor":"Peking University","startDate":"2017-04-11","conditions":"B-cell Non-Hodgkin's Lymphoma","enrollment":46},{"nctId":"NCT00504751","phase":"PHASE2","title":"Phase II Study of \"VIPER\" Chemotherapy in Rel/Ref DLBCL","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":15},{"nctId":"NCT00002601","phase":"PHASE2","title":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1994-09","conditions":"Sarcoma","enrollment":13},{"nctId":"NCT01331590","phase":"EARLY_PHASE1","title":"Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-07","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":13},{"nctId":"NCT02856997","phase":"PHASE2","title":"Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma","status":"UNKNOWN","sponsor":"Yuankai Shi","startDate":"2016-09","conditions":"Peripheral T Cell Lymphoma","enrollment":35},{"nctId":"NCT00002494","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1992-05","conditions":"Leukemia, Lymphoma","enrollment":134},{"nctId":"NCT01490060","phase":"NA","title":"Fosaprepitant in Patients Receiving Ifosfamide-based Regimen","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-05","conditions":"Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy","enrollment":47},{"nctId":"NCT00020722","phase":"PHASE2","title":"Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2007-08","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT00002546","phase":"PHASE3","title":"Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"1993-12","conditions":"Sarcoma","enrollment":216},{"nctId":"NCT00189137","phase":"PHASE2","title":"Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2004-08","conditions":"Sarcoma, Soft Tissue","enrollment":84},{"nctId":"NCT00588094","phase":"PHASE2","title":"Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-10","conditions":"Lymphoma, B-cell Non-Hodgkin's Lymphoma","enrollment":20},{"nctId":"NCT00450801","phase":"PHASE2","title":"R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-04","conditions":"Lymphoma","enrollment":22},{"nctId":"NCT00002854","phase":"PHASE1","title":"High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1994-12","conditions":"Cancer","enrollment":33},{"nctId":"NCT01501136","phase":"PHASE4","title":"Treatment of Natural Killer/T Cell Lymphoma-I/II","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2011-01","conditions":"Nasal and Nasal-type NK/T-cell Lymphoma","enrollment":200},{"nctId":"NCT01501149","phase":"PHASE4","title":"Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2011-01","conditions":"Nasal and Nasal-type NK/T-cell Lymphoma","enrollment":80},{"nctId":"NCT00658580","phase":"PHASE3","title":"Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"European Lung Cancer Working Party","startDate":"2000-04","conditions":"Small Cell Lung Carcinoma, Extensive Disease","enrollment":361},{"nctId":"NCT00072280","phase":"PHASE2","title":"Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma","status":"TERMINATED","sponsor":"Children's Oncology Group","startDate":"2004-11","conditions":"Sarcoma","enrollment":7},{"nctId":"NCT00673179","phase":"NA","title":"Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":"Osteosarcoma","enrollment":7},{"nctId":"NCT00093509","phase":"PHASE1, PHASE2","title":"MRI Sarcoma Non Invasive Thermometry","status":"COMPLETED","sponsor":"Mark Dewhirst","startDate":"1999-11","conditions":"Sarcoma","enrollment":15},{"nctId":"NCT00002804","phase":"PHASE2","title":"Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-09","conditions":"Sarcoma","enrollment":43},{"nctId":"NCT00742924","phase":"PHASE1","title":"Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-08","conditions":"Sarcoma","enrollment":24},{"nctId":"NCT00002791","phase":"PHASE2","title":"Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1997-02","conditions":"Sarcoma","enrollment":""},{"nctId":"NCT00002822","phase":"PHASE3","title":"Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"1996-03","conditions":"Lung Cancer","enrollment":400},{"nctId":"NCT00002802","phase":"PHASE3","title":"Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"1990-07","conditions":"Neuroblastoma","enrollment":500},{"nctId":"NCT01258634","phase":"PHASE1","title":"A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2010-07","conditions":"Osteosarcoma, Lung Metastases","enrollment":2},{"nctId":"NCT00292695","phase":"PHASE2","title":"A Phase II Study of Nasal NK/T-cell Lymphoma","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2006-05","conditions":"Lymphoma","enrollment":33},{"nctId":"NCT00002516","phase":"PHASE3","title":"Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma","status":"UNKNOWN","sponsor":"University Hospital Muenster","startDate":"1992-07","conditions":"Sarcoma","enrollment":""},{"nctId":"NCT00002816","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-12","conditions":"Leukemia","enrollment":120},{"nctId":"NCT00006373","phase":"PHASE2","title":"Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2000-02","conditions":"Lymphoma","enrollment":27},{"nctId":"NCT00126191","phase":"PHASE2","title":"Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-07","conditions":"Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma","enrollment":10},{"nctId":"NCT00801918","phase":"PHASE2","title":"Denileukine Diftitox for Relapsed ALCL","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2008-12","conditions":"Anaplastic Large-Cell Lymphoma","enrollment":""},{"nctId":"NCT00006708","phase":"PHASE3","title":"S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2000-10","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT00410488","phase":"NA","title":"Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Sarcoma, Nausea, Vomiting","enrollment":51},{"nctId":"NCT00823719","phase":"PHASE2","title":"Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Lymphoma, Large-Cell, Diffuse","enrollment":61},{"nctId":"NCT01333605","phase":"PHASE2","title":"IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2011-04","conditions":"Hodgkin Lymphoma","enrollment":43},{"nctId":"NCT00622349","phase":"PHASE3","title":"Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"European Lung Cancer Working Party","startDate":"2004-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":707},{"nctId":"NCT00551122","phase":"PHASE1, PHASE2","title":"Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors","status":"UNKNOWN","sponsor":"University of Southampton","startDate":"2006-11","conditions":"Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer","enrollment":23},{"nctId":"NCT01752517","phase":"","title":"Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2012-12","conditions":"Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT01749072","phase":"PHASE2","title":"Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2012-12","conditions":"Non-small Cell Lung Cancer, Effects of Chemotherapy","enrollment":120}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"NEUTROPENIA"},{"count":6,"reaction":"FEBRILE NEUTROPENIA"},{"count":5,"reaction":"DISEASE PROGRESSION"},{"count":5,"reaction":"THROMBOCYTOPENIA"},{"count":4,"reaction":"ANAEMIA"},{"count":4,"reaction":"FEBRILE BONE MARROW APLASIA"},{"count":2,"reaction":"ASPERGILLUS INFECTION"},{"count":2,"reaction":"ATRIAL FIBRILLATION"},{"count":2,"reaction":"CYTOPENIA"},{"count":2,"reaction":"DYSPHAGIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ifosfamide + Mesna","genericName":"Ifosfamide + Mesna","companyName":"Lymphoma Study Association","companyId":"lymphoma-study-association","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ifosfamide is an alkylating agent that cross-links DNA to kill cancer cells, while mesna is a protective agent that binds to toxic metabolites to reduce bladder toxicity. Used for Lymphoma (as part of combination chemotherapy regimen in phase 3 study).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}